Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.dsi.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.
For more information, please visit www.daiichisankyo.com
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
305 articles with Daiichi Sankyo
-
Ken Keller Named President, U.S. Commercial, Daiichi Sankyo, Inc.
4/18/2014
-
Astellas Pharma Inc. And Daiichi Sankyo, Inc. Form Compound Library Sharing Partnership
3/20/2014
-
Provepharm Announces That Its Partner In Japan, Daiichi Sankyo, Inc. Has Filed An NDA For The Marketing Of The Methylene Blue Injection Medicinal Product In Japan, Made Out Of Proveblue® Methylene Blue Active Substance
3/19/2014
-
Daiichi Sankyo, Inc. Pledges Bold Action On Ranbaxy Laboratories Production Problems
1/31/2014
-
Daiichi Sankyo, Inc. Submits SAVAYSA (Edoxaban) Tablets New Drug Application To The FDA For Once-Daily Use For Stroke Risk Reduction In Atrial Fibrillation And For The Treatment And Prevention Of Recurrence Of Venous Thromboembolism
1/14/2014
-
Pieris Achieves Fourth Milestone Payment In Daiichi Sankyo, Inc. Collaboration To Develop Anticalin® Therapeutics
1/13/2014
-
Daiichi Sankyo, Inc., Virtici And Celdara Medical Announce Collaboration To Identify And Progress High Potential Therapeutics
1/8/2014
-
Daiichi Sankyo, Inc. Submits Edoxaban Marketing Authorization Application To The EMA For Once-Daily Use For Stroke Prevention In Atrial Fibrillation And For The Treatment And Prevention Of Recurrence Of Venous Thromboembolism
1/7/2014
-
Daiichi Sankyo, Inc. To Help Ranbaxy Laboratories Meet FDA Norms
12/19/2013
-
Phase 3 Data Show Daiichi Sankyo, Inc.'s Once-Daily Edoxaban Lowered Incidence Of VTE Recurrence And Clinically Relevant Bleeding Compared To Warfarin In A Large Subgroup Of Patients With Cancer
12/9/2013
-
Daiichi Sankyo, Inc. Blood Thinner Succeeds In Major Study; Gets Set To Face Rivals
11/20/2013
-
Daiichi Sankyo, Inc.'s Once-Daily Edoxaban Meets Primary Efficacy Endpoint For Stroke Prevention And Superiority For The Principal Safety Endpoint Compared To Warfarin For Patients With Atrial Fibrillation In A Phase 3 Clinical Trial
11/19/2013
-
Study Supporting Daiichi Sankyo, Inc. Promotional Materials Pummeled By FDA In New Untitled Letter
11/13/2013
-
Pieris Receives Third Milestone Payment In Daiichi Sankyo, Inc. Collaboration To Develop Anticalin® Therapeutics
11/12/2013
-
Singh Brothers Of Ranbaxy Laboratories Concealed Facts While Selling Stake: Daiichi Sankyo, Inc.
11/11/2013
-
No Criminal Case Against Ranbaxy Laboratories, Daiichi Sankyo, Inc.
11/1/2013
-
Daiichi Sankyo, Inc. Makes Two New Executive Appointments
10/4/2013
-
Daiichi Sankyo, Inc.'s Edoxaban Matched Warfarin in Study
9/3/2013
-
American Regent Inc.'s Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Iron Deficiency Anemia
7/26/2013
-
Daiichi Sankyo, Inc. Release: New Guidelines From the American Association of Clinical Endocrinologists (AACE) Identify Welchol® (colesevelam HCI) for Lowering Both A1C and LDL-Cholesterol in Patients With Type 2 Diabetes
6/7/2013